16 completed, 2 terminated. 18 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 16, Terminated 2 |
| Phase 2 | 3 | Completed 3 |
Follow Zofran: new trials by email Literature Review of Zofran trials Research Report on Zofran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR - Kita-kyushu Lung Cancer Antigen 1, Human | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2022-03-08 | 2025-12-02 |
| PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers PLX038, Rucaparib, Ondansetron - Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2020-04-08 | 2026-08-26 |
| Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran Bremelanotide, Zofran, Placebo - Nausea | Phase 1 | Completed | AMAG Pharmaceuticals, Inc. | 228 | 2019-06-17 | 2022-04-04 |
| Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas LMP744, Ondansetron, Olanzapine - Solid Tumors, Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2017-02-27 | 2024-12-10 |
| E7 TCR T Cells for Human Papillomavirus-Associated Cancers E7 TCR cells, Aldesleukin, Fludarabine - Papillomavirus Infections, Cervical Intraepithelial Neoplasia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 224 | 2017-01-27 | 2026-03-09 |
| The Effects of Ondansetron on Brain Function ondansetron, placebo - Brain Function, Healthy Adults | Phase 1 | Completed | Icahn School of Medicine at Mount Sinai | 54 | 2015-08-01 | 2017-04-11 |
| Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting Ondansetron with1:1 ORA - sweet. - Gastroenteritis | Phase 1 | Completed | Hamad Medical Corporation | 40 | 2014-09-01 | 2015-06-17 |
| Ondansetron for Pediatric Mild Traumatic Brain Injury Ondansetron, PLacebo - Traumatic Brain Injury, Brain Concussion | Phase 1 | Completed | St. Justine's Hospital | 16 | 2013-03-01 | 2015-09-29 |
| How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women Ondansetron - Postoperative Nausea | Phase 1 / Phase 2 | Completed | Stanford University | 100 | 2013-01-01 | 2015-06-01 |
| Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers Ondansetron, Ondansetron + Hylenex, Zofran ODT - Healthy | Phase 1 | Completed | Halozyme Therapeutics | 12 | 2012-02-01 | 2014-01-24 |
| To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects ondansetron, moxifloxacin, saline - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Completed | GlaxoSmithKline | 60 | 2011-08-16 | 2017-11-13 |
| A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron - Chemotherapy-Induced Nausea and Vomiting | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 92 | 2009-02-05 | 2018-09-25 |
| A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148) Aprepitant, Ondansetron - Postoperative Nausea and Vomiting | Phase 1 | Completed | Merck Sharp & Dohme LLC | 98 | 2009-01-26 | 2021-01-26 |
| Two Way Bioequivalence Study Under Fed Conditions Ondansetron (ODFS), Ondansetron (ODT) - Healthy | Phase 1 | Completed | MonoSol Rx | 48 | 2008-10-01 | 2017-05-02 |
| Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) SCH 727965, Aprepitant, Ondansetron - Solid Tumors, Lymphoma, Non-Hodgkin | Phase 1 | Completed | Merck Sharp & Dohme LLC | 81 | 2006-10-11 | 2017-10-23 |
| Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions Ondansetron, Zofran - Healthy | Phase 1 | Completed | Par Pharmaceutical, Inc. | 24 | 2003-10-01 | 2008-04-16 |
| Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions Ondansetron, Zofran - Healthy | Phase 1 | Completed | Par Pharmaceutical, Inc. | 32 | 2002-08-01 | 2008-04-11 |
| Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions Ondansetron, Zofran - Healthy | Phase 1 | Completed | Par Pharmaceutical, Inc. | 18 | 2002-08-01 | 2008-04-11 |
Vomiting (3) · Fasting (2) · Nausea (2) · Postoperative Nausea and Vomiting (2) · Brain Concussion (1) · Brain Injuries, Traumatic (1) · Carcinoma (1) · Carcinoma in Situ (1) · Emergencies (1) · Gastroenteritis (1) · Lecithin Cholesterol Acyltransferase Deficiency (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1)
National Cancer Institute (NCI) (4) · Merck Sharp & Dohme LLC (3) · Par Pharmaceutical, Inc. (3) · AMAG Pharmaceuticals, Inc. (1) · GlaxoSmithKline (1) · Halozyme Therapeutics (1) · Hamad Medical Corporation (1) · Icahn School of Medicine at Mount Sinai (1) · MonoSol Rx (1) · St. Justine's Hospital (1) · Stanford University (1)
United States (10) · Canada (2) · Brazil (1) · India (1) · Mexico (1) · Spain (1) · Turkey (Türkiye) (1)
Christian Aumais (2) · Scott M Norberg, D.O. (2) · Alice P Chen, M.D. (1) · David R. Drover, MD (1) · Emily Stern, PhD (1) · Eric Sicard (1) · James Gulley, M.D. (1) · Jocelyn Gravel, MD (1) · Khalid Al-Ansari, MD, FRCPC, FAAP (1) · Samuel S Dychter, MD (1) · Sudershan Vishwanath (1)
PMID 23053255, PMID 24486335, PMID 25670522, PMID 25770814, PMID 28859059, PMID 32839657, PMID 33558725, PMID 40439882, PMID 40856942
2008 (1)